Neogen Corporation is classed by the SEC under In Vitro & In Vivo Diagnostic Substances (industry code 2835), based in Lansing, MI. In its latest annual figures on file, for the fiscal year ended 2025-05-31, it reported revenue of $895 million and a loss of $1.1 billion (its filed statements).
Product businessIn Vitro & In Vivo Diagnostic SubstancesLansing, MIfilings since 19959 of 9 filed
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2835, In Vitro & In Vivo Diagnostic Substances); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.5 out of ten, 9 of 9 metrics filed: past 6.2 out of ten, present 5.7 out of ten, future 4.3 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 5.8 out of ten. 2 warning events since 2017; the latest 2025-01-10. 58th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 7.4 out of ten. +10.4% a year over 10 filed years; profitable in 6 of 10. 74th percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 4.5 out of ten. Share count grew 4.8% a year. 0% of cash flow returned. Insiders: 0 sales, 7 purchases. 45th percentile among 5 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Financial health (present): 6.5 out of ten. ROE 0%: lost 0¢ per shareholder dollar. Leverage 37%: owes 37¢ per asset dollar. 65th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 6.9 out of ten. top 31% of 17 in its family; net margin -0.9%. 69th percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 2.5 out of ten. bottom 25% of 15 in its family for leadership; chief executive since 2025. 25th percentile among 15 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 3.5 out of ten. bottom 35% of 16 in its family for room to expand. 35th percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 3.6 out of ten. bottom 36% of 17 in its family for growth drivers. 36th percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 7.1 out of ten. top 29% of 16 in its family for expectations against reality. 71st percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-07-30 for the period ended 2026-05-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-10-07 for the period ended 2026-08-31 (on EDGAR). Newest results release: Form 8-K filed 2026-10-06 (on EDGAR). Newest filing: Form 4, 2026-10-09. Filings on record since 1995. Read from EDGAR 2026-10-12.
Where the revenue comes from
Lines of business in fiscal 2026: Food Safety 74%, Animal Safety 26%. By geography: Outside the United States 51%, United States 49%. As tagged in its annual report (Form 10-K, filed 2026-07-30).
Who runs it
Nassif, Mikheal (CEO); Adent, John Edward (Former CEO); Ranalli, Tamara A. (Senior Vice President); Riggsbee, Richard Bryan (CFO); Naemura, David H. (Former CFO); Jones, Douglas Edward (Former COO); Moylan, John Patrick (Chief Accounting Officer); Stacey, Jennifer Evans (Chief Legal Officer); Rocklin, Amy M (Former Chief Legal Officer); Borel, James C (director); and 10 more. 20 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-09.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.